Asthma Clinical Trial
Official title:
Hospital-Level Care at Home for Acutely Ill Adults: A Randomized Controlled Trial
NCT number | NCT03203759 |
Other study ID # | P001337 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 6, 2017 |
Est. completion date | May 15, 2018 |
Verified date | August 2018 |
Source | Brigham and Women's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improved patient experience.
Status | Completed |
Enrollment | 91 |
Est. completion date | May 15, 2018 |
Est. primary completion date | February 17, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Resides within either a 5-mile or 20 minute driving radius of emergency department - Has capacity to consent to study OR can assent to study and has proxy who can consent - >= 18 years-old - Can identify a potential caregiver who agrees to stay with patient for first 24 hours of admission. Caregiver must be competent to call care team if a problem is evident to her/him. After 24 hours, this caregiver should be available for as-needed spot checks on the patient. This criterion may be waived for highly competent patients at the patient and clinician's discretion. - Primary or possible diagnosis of cellulitis, heart failure, complicated urinary tract infection, pneumonia, COPD/asthma, other infection, chronic kidney disease, malignant pain, diabetes and its complications, gout flare, hypertensive urgency, previously diagnosed atrial fibrillation with rapid ventricular response, anticoagulation needs, or a patient who desires only medical management that requires inpatient admission, as determined by the emergency room team. Exclusion Criteria: - Undomiciled - No working heat (October-April), no working air conditioning if forecast > 80°F (June-September), or no running water - On methadone requiring daily pickup of medication - In police custody - Resides in facility that provides on-site medical care (e.g., skilled nursing facility) - Domestic violence screen positive - Acute delirium, as determined by the Confusion Assessment Method - Cannot establish peripheral access in emergency department (or access requires ultrasound guidance) - Secondary condition: end-stage renal disease, acute myocardial infarction, acute cerebral vascular accident, acute hemorrhage - Primary diagnosis requires multiple or routine administrations of intravenous narcotics for pain control - Cannot independently ambulate to bedside commode - As deemed by on-call medical doctor, patient likely to require any of the following procedures: computed tomography, magnetic resonance imaging, endoscopic procedure, blood transfusion, cardiac stress test, or surgery - High risk for clinical deterioration - Home hospital census is full (maximum 5 patients at any time) |
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Women's Faulkner Hospital | Boston | Massachusetts |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Brigham and Women's Hospital | Smiths Medical, Vital Connect |
United States,
Counsell SR, Holder CM, Liebenauer LL, Palmer RM, Fortinsky RH, Kresevic DM, Quinn LM, Allen KR, Covinsky KE, Landefeld CS. Effects of a multicomponent intervention on functional outcomes and process of care in hospitalized older patients: a randomized controlled trial of Acute Care for Elders (ACE) in a community hospital. J Am Geriatr Soc. 2000 Dec;48(12):1572-81. — View Citation
Cryer L, Shannon SB, Van Amsterdam M, Leff B. Costs for 'hospital at home' patients were 19 percent lower, with equal or better outcomes compared to similar inpatients. Health Aff (Millwood). 2012 Jun;31(6):1237-43. doi: 10.1377/hlthaff.2011.1132. — View Citation
Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009 Apr;5(4):210-20. doi: 10.1038/nrneurol.2009.24. Review. — View Citation
Hung WW, Ross JS, Farber J, Siu AL. Evaluation of the Mobile Acute Care of the Elderly (MACE) service. JAMA Intern Med. 2013 Jun 10;173(11):990-6. doi: 10.1001/jamainternmed.2013.478. — View Citation
Leff B, Burton L, Mader SL, Naughton B, Burl J, Inouye SK, Greenough WB 3rd, Guido S, Langston C, Frick KD, Steinwachs D, Burton JR. Hospital at home: feasibility and outcomes of a program to provide hospital-level care at home for acutely ill older patients. Ann Intern Med. 2005 Dec 6;143(11):798-808. — View Citation
Montalto M. The 500-bed hospital that isn't there: the Victorian Department of Health review of the Hospital in the Home program. Med J Aust. 2010 Nov 15;193(10):598-601. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Total reimbursement, 30-day post discharge | Exploratory | Day of admission to 30-days post-discharge | |
Other | Intravenous medications, days | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Intravenous fluids, days | Exploratory; the number of days intravenous fluids (for example, normal saline) were received by the patient. | From date of admission to date of discharge, an expected average of 4 days | |
Other | Intravenous diuretics, days | Exploratory; the number of days intravenous diuretics (for example, furosemide) were received by the patient. | From date of admission to date of discharge, an expected average of 4 days | |
Other | Intravenous antibiotics, days | Exploratory; the number of days intravenous antibiotics (for example, ceftriaxone) were received by the patient. | From date of admission to date of discharge, an expected average of 4 days | |
Other | Supplemental oxygen required, days | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Nebulizer treatment, days | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Medical Doctor sessions, # notes | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Consultant sessions, # notes | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Physical therapy/occupational therapy sessions, # notes | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Primary care provider follow-up within 14 days, y/n | Exploratory | Day of discharge to 14 days later | |
Other | Skilled nursing facility utilization, days | Exploratory; the number of days a patient spent in a skilled nursing facility. | Day of discharge to 30 days later | |
Other | Home health utilization, days | Exploratory | Day of discharge to 30 days later | |
Other | Fall, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hospital-acquired deep vein thrombosis or pulmonary embolism, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hospital-acquired pressure ulcer, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hospital-acquired thrombophlebitis at peripheral IV site, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hospital-acquired catheter-associated urinary tract infection, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hospital-acquired Clostridium difficile infection, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hospital-acquired methicillin resistant staphylococcus aureus infection, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | All-cause mortality, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Unplanned mortality, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Post-discharge all-cause mortality, y/n | Exploratory | Day of discharge to 30 days later | |
Other | Post-discharge unplanned mortality, y/n | Exploratory | Day of discharge to 30 days later | |
Other | New arrhythmia, y/n | Heart failure patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hypokalemia, y/n | Heart failure patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Acute Kidney Injury, y/n | Heart failure patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Mean Likert scale pain score, 0-10 | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hours of sleep per night, # | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hours of activity per night, # | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Hours of sitting upright per night, # | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Pneumococcal vaccination if appropriate, y/n | Pneumonia patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Influenza vaccination if appropriate, y/n | Pneumonia patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Smoking cessation counseling if appropriate, y/n | Pneumonia and heart failure patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Evaluation of ejection fraction as assessed by echocardiogram or other appropriate study, scheduled or completed, if not done within 1 year; y/n | Heart failure patients only; Exploratory; Whether or not an appropriate study occurred and/or was scheduled if not done within 1 year; appropriate studies include cardiac magnetic resonance imaging, radionuclide ventriculography, single photon emission computed tomography myocardial perfusion imaging, or left ventriculography | From date of admission to date of discharge, an expected average of 4 days | |
Other | Angiotensin converting enzyme inhibitor or angiotensin receptor blocker for heart failure with reduced ejection fraction (ejection fraction < 40%), y/n | Heart failure patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Beta blocker for heart failure with reduced ejection fraction (ejection fraction < 40%), y/n | Heart failure patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Aldosterone antagonist for heart failure with reduced ejection fraction (ejection fraction < 40%), y/n | Heart failure patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Lipid lowering for coronary artery disease, peripheral vascular disease, cerebrovascular accident, or diabetes, y/n | Heart failure patients only; Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Smoking status post-discharge; current/never/quit | Heart failure and pneumonia patients only; Exploratory; Self-report of smoking status: current/never/quit. | From date of admission to date of discharge, an expected average of 4 days | |
Other | Use of inappropriate medications in the elderly, y/n | Exploratory; using Screening Tool of Older Persons' potentially inappropriate Prescriptions (STOPP) and Beers criteria | From date of admission to date of discharge, an expected average of 4 days | |
Other | Use of Foley catheter, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | Use of restraints, y/n | Exploratory | From date of admission to date of discharge, an expected average of 4 days | |
Other | >3 medications added to medication list, y/n | Exploratory; comparison made between preadmission and discharge medication list | Date of discharge, an expected average of 4 days after the date of admission | |
Other | Patient health questionnaire-2, score | Exploratory | At admission, at discharge (an expected average of 4 days after the date of admission), and at 30 days after discharge | |
Other | Patient-Reported Outcomes Measurement Information System Emotional Support Short Form 4a, score | Exploratory | At admission, at discharge (an expected average of 4 days after the date of admission), and at 30 days after discharge | |
Other | Days at home since discharge | Exploratory | 30 days after discharge | |
Other | Walk around ward/home, y/n | Exploratory | Date of discharge, an expected average of 4 days after the date of admission | |
Other | Get to (non-commode) bathroom, y/n | Exploratory | Date of discharge, an expected average of 4 days after the date of admission | |
Other | Walk 1 flight of stairs, y/n | Exploratory | Date of discharge, an expected average of 4 days after the date of admission | |
Other | Visit with friends/family, y/n | Exploratory | Date of discharge, an expected average of 4 days after the date of admission | |
Other | Walk outside around my home, y/n | Exploratory | Date of discharge, an expected average of 4 days after the date of admission | |
Other | Go shopping, y/n | Exploratory | Date of discharge, an expected average of 4 days after the date of admission | |
Other | Time from admission decision to assessment by research assistant, minutes | Exploratory | On the first day of admission, a maximum 24 hour period | |
Other | Time from research assistant assessment to emergency department dismissal, minutes | Exploratory | On the first day of admission, a maximum 24 hour period | |
Other | Time from arrival home or to floor and medical doctor evaluation, minutes | Exploratory | On the first day of admission, a maximum 24 hour period | |
Other | Time from arrival home or to floor and registered nurse evaluation, minutes | Exploratory | On the first day of admission, a maximum 24 hour period | |
Other | Mean registered nurse to patient ratio | Exploratory, intervention arm only | From date of admission to date of discharge, an expected average of 4 days | |
Other | Total registered nurse visits, # | Exploratory, intervention arm only | From date of admission to date of discharge, an expected average of 4 days | |
Other | Total "on call" medical doctor interactions (video or phone), # | Exploratory, intervention arm only | From date of admission to date of discharge, an expected average of 4 days | |
Other | Total "on call" medical doctor in-person visits, # | Exploratory, intervention arm only | From date of admission to date of discharge, an expected average of 4 days | |
Other | Duration of 1st registered nurse visit, minutes | Exploratory, intervention arm only | On the first day of admission, a maximum 24 hour period | |
Other | Mean duration of subsequent registered nurse visit, minutes | Exploratory, intervention arm only | From date of admission to date of discharge, an expected average of 4 days | |
Primary | Total direct cost of hospitalization, $ | From date of admission to date of discharge, an expected average of 4 days | ||
Secondary | Direct margin, $ | Direct margin from total cost of hospitalization | From date of admission to date of discharge, an expected average of 4 days | |
Secondary | Direct margin, modeled with backfill | Backfill uses a model that estimates the cost of patients who take the place of home hospital patients | From date of admission to date of discharge, an expected average of 4 days | |
Secondary | Total cost, 30-day post discharge | Day of admission to 30-days post-discharge | ||
Secondary | Length of stay, days | From date of admission to date of discharge, an expected average of 4 days | ||
Secondary | Imaging, # | Count of any diagnostic imaging (for example, x-ray, computed tomography, magnetic resonance, ultrasound, and nuclear imaging) that occurred through the course of the hospitalization. | From date of admission to date of discharge, an expected average of 4 days | |
Secondary | Lab orders, # | Count of any lab order (for example, basic metabolic panel, complete blood count, hepatic function panel) that occurred through the course of the hospitalization. | From date of admission to date of discharge, an expected average of 4 days | |
Secondary | All-cause readmission(s) after index, # | Day of discharge to 30 days later | ||
Secondary | All-cause readmission(s) after index, y/n | Day of discharge to 30 days later | ||
Secondary | Unplanned readmission(s) after index, # | Day of discharge to 30 days later | ||
Secondary | Unplanned readmission(s) after index, y/n | Day of discharge to 30 days later | ||
Secondary | Emergency Department observation stay(s) after index hospitalization, # | Day of discharge to 30 days later | ||
Secondary | Emergency Department observation stay(s) after index hospitalization, y/n | Day of discharge to 30 days later | ||
Secondary | Emergency Department visit(s) after index hospitalization, # | Day of discharge to 30 days later | ||
Secondary | Emergency Department visit(s) after index hospitalization, y/n | Day of discharge to 30 days later | ||
Secondary | Delirium, y/n | From date of admission to date of discharge, an expected average of 4 days | ||
Secondary | Transfer back to hospital, y/n | Intervention arm only | From date of admission to date of discharge, an expected average of 4 days | |
Secondary | Hours of sleep per day, # | From date of admission to date of discharge, an expected average of 4 days | ||
Secondary | Hours of activity per day, # | From date of admission to date of discharge, an expected average of 4 days | ||
Secondary | Hours of sitting upright per day, # | From date of admission to date of discharge, an expected average of 4 days | ||
Secondary | Steps per day, # | From date of admission to date of discharge, an expected average of 4 days | ||
Secondary | EuroQol -5D-5L, composite score | At admission, at discharge (the day the patient leaves the hospital environment), and at 30 days after discharge | ||
Secondary | Short Form 1 | 1-5 Likert scale | 30 days prior to admission (asked on day of admission), at admission, at discharge (the day the patient leaves the hospital environment), and at 30 days after discharge | |
Secondary | Activities of daily living, score | 30 days prior to admission (asked on day of admission), at admission, at discharge (the day the patient leaves the hospital environment), and at 30 days after discharge | ||
Secondary | Instrumental activities of daily living, score | 30 days prior to admission (asked on day of admission), at admission, at discharge (the day the patient leaves the hospital environment), and at 30 days after discharge | ||
Secondary | 3-item Care Transition Measure, score | 30 days after discharge | ||
Secondary | Picker Experience Questionnaire, score | 30 days after discharge | ||
Secondary | Global satisfaction with care, score | 30 days after discharge | ||
Secondary | Qualitative interview | 30 days after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|